Core Viewpoint - The biotechnology sector in the STAR Market is showing positive momentum, with significant increases in the performance of key stocks and the STAR Market Biopharmaceutical Index [1][4]. Group 1: Market Performance - As of July 31, 2025, the STAR Market Biopharmaceutical Index rose by 0.57%, with notable stock performances including Teva Biopharma up by 8.39% and Maiwei Biopharma up by 6.68% [1]. - The Jiashi STAR Market Biopharmaceutical ETF recorded a 0.59% increase, indicating active market trading with a turnover rate of 20.3% and a transaction volume of 44.83 million yuan [3]. Group 2: Fund Performance - The Jiashi STAR Market Biopharmaceutical ETF has seen a weekly average transaction volume of 48.48 million yuan, ranking first among comparable funds [3]. - Over the past week, the Jiashi ETF's scale increased by 17.98 million yuan, and its shares grew by 12.50 million, both leading among comparable funds [3]. - The Jiashi ETF's net value increased by 58.87% over the past year, placing it in the top 9.79% among 2,941 index equity funds [3]. Group 3: Key Stocks and Weightings - As of June 30, 2025, the top ten weighted stocks in the STAR Market Biopharmaceutical Index accounted for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [4][6]. - The performance of these stocks varied, with some experiencing declines while others, like Yifang Biopharma, saw increases of 5.85% [6]. Group 4: Industry Outlook - According to Zhongyin Securities, the pharmaceutical sector is witnessing a shift in policy attitudes, with improvements in centralized procurement rules and a growing pipeline of innovative drugs entering the market [6]. - The industry is expected to emerge from a low point, with potential for valuation re-rating as policies and corporate profitability improve [6].
科创医药ETF嘉实(588700)逆市红盘，机构：医药板块有望迎来估值重塑机会
Xin Lang Cai Jing·2025-07-31 05:31